IP Library Granted Patent US 9,150,837
Granted Patent B2
US 9,150,837 · App. 13/929,222 · Granted Oct 6, 2015

Polyethylene glycolated superoxide dismutase mimetics

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,150,837
App. No.
13/929,222
Granted
Oct 6, 2015
Kind
B2
Abstract

Compounds and methods for utilizing compounds comprising a superoxide dismutase mimetic covalently linked to polyethylene glycol. Methods are also provided for preparing a superoxide dismutase mimetic covalently linked to a polyethylene glycol, the methods comprising reacting an activated polyethylene glycol with a superoxide dismutase mimetic, or alternatively, reacting a superoxide dismutase mimetic with an activated polyethylene glycol. A method is also provided for preventing or treating a disease or disorder in which superoxide anions are implicated, comprising administering to a subject in need thereof, a therapeutically effective amount of a compound comprising a superoxide dismutase mimetic covalently linked to a polyethylene glycol. Methods of determining the safety and efficacy of the compounds are also provided. Methods for determining the safety and efficacy can include methods in lab animals and humans.

Claims (28)

1. A method for treating a disease or disorder affected by superoxide dismutase activity, the method comprising:

administering a therapeutically effective amount of a compound comprising a superoxide dismutase mimetic covalently linked to a polyethylene glycol to a subject in need thereof,

wherein the disease or disorder is selected from the group consisting of severe chronic pain, hyperalgesia, central pain, and peripheral pain.

2. The method according to claim 1 , wherein the subject is a mammal; or said mammal is a human.

3. The method according to claim 1 , wherein the disease or disorder is selected from the group consisting of hyperalgesia and chronic pain.

4. The method according to claim 1 , wherein the disease or disorder is central pain or peripheral pain.

5. The method according to claim 1 , wherein superoxide dismutase mimetic comprises:

6. The method according to claim 1 , wherein the superoxide dismutase mimetic comprises:

and

n is between about 7 and about 1,000.

7. The method according to claim 1 , wherein the superoxide dismutase mimetic is selected from the group consisting of:

and

n is between about 7 and about 1,000.

8. The method according to claim 7 , wherein n is about 23.

9. The method according to claim 7 , wherein n is about 45.

10. The method according to claim 7 , wherein n is about 114.

11. The method according to claim 7 , wherein n is about 455.

12. The method according to claim 7 , wherein the polyethylene glycol has a molecular weight from about 300 Da to about 44 kDa.

13. The method according to claim 8 , wherein:

the polyethylene glycol has a molecular weight from about 300 Da to about 44 kDa;

the polyethylene glycol has a molecular weight from about 2500 Da to about 40 kDa;

the polyethylene glycol has a molecular weight from about 1 kDa to about 35 kDa;

the polyethylene glycol has a molecular weight from about 5 kDa to about 25 kDa;

the polyethylene glycol has a molecular weight from about 800 Da to about 1200 Da;

the polyethylene glycol has a molecular weight from about 1800 Da to about 2200 Da;

the polyethylene glycol has a molecular weight from about 4800 Da to about 5200 Da;

the polyethylene glycol has a molecular weight from about 9800 Da to about 10,200 Da; or

the polyethylene glycol has a molecular weight from about 1800 to about 2200 kDa.

Assignments (9)
LICENSE Recorded Aug 29, 2018
From: INOTEK PHARMACEUTICALS CORPORATION
To: GALERA THERAPEUTICS, LLC
Reel/Frame 046979/0861 →
BILL OF SALE Recorded Aug 29, 2018
From: ACTIVBIOTICS, INC.; METAPHORE PHARMACEUTICALS, INC.
To: KEREOS, INC.; INOTEK PHARMACEUTICALS CORPORATION
Reel/Frame 047092/0295 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Aug 29, 2018
From: KEREOS, INC.
To: GALERA THERAPEUTICS, LLC
Reel/Frame 046740/0793 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Aug 29, 2018
From: INOTEK PHARMACEUTICALS CORPORATION
To: GALERA THERAPEUTICS, LLC
Reel/Frame 046741/0080 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Mar 27, 2015
From: KEREOS, INC.
To: GALERA THERAPEUTICS, LLC
Reel/Frame 035276/0653 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Mar 5, 2015
From: ACTIVBIOTICS, INC. AND METAPHORE PHARMACEUTICALS, INC.
To: KEREOS, INC.; INOTEK PHARMACEUTICALS CORPORATION
Reel/Frame 035095/0001 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Mar 5, 2015
From: INOTEK PHARMACEUTICALS CORPORATION
To: GALERA THERAPEUTICS LLC
Reel/Frame 035095/0526 →
CHANGE OF NAME Recorded Mar 5, 2015
From: GALERA THERAPEUTICS LLC
To: GALERA LABS LLC
Reel/Frame 035095/0612 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Mar 5, 2015
From: SALVEMINI, DANIELA; NEUMANN, WILLIAM L.; TREMONT, SAMUEL; UDIPI, KISHORE; POREDDY, AMRUTA REDDY
To: ACTIVBIOTICS, INC.
Reel/Frame 035094/0602 →